⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294981 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL1162939 | 0.65 | — | — | |
| SCHEMBL11258608 | 0.62 | — | — | |
| Bicarbonate SCHEMBL31738461 | 0.60 | — | — | |
| Phosphoric Acid SCHEMBL31305342 | 0.50 | — | — | |
| Urea C 13 SCHEMBL12476878 | 0.48 | — | — | |
| SCHEMBL8938 | 0.48 | — | — | |
| Urea SCHEMBL7756359 | 0.48 | LMNA (1.00) | — | |
| Urea SCHEMBL20641124 | 0.48 | LMNA (1.00) | — | |
| Urea SCHEMBL411583 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367111-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-2220078-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | Amgen, Inc (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009058267-A2 | BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |